You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of a Molecular Diagnostic to Identify Dangerous Intracranial Aneurysms
SBC: NEUROVASCULAR DIAGNOSTICS, INC. Topic: 103Project SummaryIntracranial aneurysm (IA) rupture is the primary cause of non-traumatic subarachnoid hemorrhage, a catastrophic event that carries high rates of mortality (rt50%) and permanent disability (rt50% among survivors). When an unruptured IA is discovered, clinicians face the difficult decision of whether or not it should be treated. Since rupture rates are low (risk of rupture ~ 0.5-1% p ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development and clinical assessment of a robust, 3D printed titanium, myoelectric powered prosthetic digit system
SBC: POINT DESIGNS, LLC Topic: 106ABSTRACT Approximately 600,000 people live with partial hand amputations in the United States, with an estimated 14,500 new cases occurring each year. Despite the advances in miniaturized electronics and motors, there has been very little advancement in mechatronic prosthetic digits for this underserved patient population. In fact, to date, there is only one myoelectric prosthetic option for patie ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Neuro-exergaming for the Prevention and Remediation of Decline due to Parkinson's Disease: Clinical Trial of the Interactive Physical and Cognitive Exercise System (iPACES v3)
SBC: iPACES LLC Topic: NINDSPROJECT SUMMARY/ABSTRACT Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder after Alzheimer’s disease with prevalence estimated at 0.3% in the general population and at 1% in individuals over age 60 (Getz and Levin, 2017). In addition to the cardinal motor features associated with this illness, individuals with PD also experience cognitive decline. While estimates ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Therapy and Prophylaxis for Genital Tract Infection
SBC: THERAPYX, INC. Topic: NIAIDABSTRACT GneX12 is a patented therapeutic vaccine in development specifically for women with Neisseria gonorrhoeae (gonorrhea) infection. It is a novel formulation of recombinant human interleukin-12 (IL-12) encapsulated in biodegradable sustained release micro-particles. It is meant to be given in conjunction with standard of care antibiotics to turn infections into live vaccines that generate pr ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Comparative testing of tatCN19o for neuroprotection in rodent tMCAo
SBC: NEUREXIS THERAPEUTICS, INC. Topic: NINDSProject Summary/Abstract Focal cerebral ischemia (stroke) afflicts nearly 800,000 Americans each year and often results in permanent cognitive impairment or death. Efforts in developing a cerebroprotective stroke therapy have largely resulted in disappointment: the only approved pharmacological therapy is hemolytic treatment with tissue plasminogen activator (tPA; alteplase). In this project, we w ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
IL-10NanoCap® for Therapy of Familial Adenomatous Polyposis
SBC: THERAPYX, INC. Topic: 300Abstract This SBIR Phase IIb proposal builds on the success of our Fast-track award supporting the pre-clinical development of FAPXIL, an oral sustained-release micro-particulate formulation of Interleukin-10 for the treatment of Familial Adenomatous Polyposis (FAP). The Phase I portion of our Fast-track project provided validation of our large-batch methods and activity in a clinically-relevant m ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Non-Clinical Pharmacology of CX-01
SBC: Ceramedix Holding, LLC Topic: NIAIDDevelopment of radiation medical countermeasures (MCM) has become a national security priority owing to such threats as radiological dispersal devices (i.e., “dirty bomb”) and nuclear accidents, which may be caused by extreme weather (such as occurred in Fukushima, Japan in 2011). Radiation exposure can be potentially lethal via the hematopoietic-acute radiation syndrome (H-ARS) and the gastro ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Research and Development to Establish a Small Animal Model as a Significant Resource of High-Value Single-Domain Antibodies
SBC: INGENIOUS TARGETING LABORATORY INC. Topic: NIAIDProject Summary Genetically-modified mouse models have proven to be essential for the production of antibody-related biological drugs (biologics). To date, the majority of biologics originate from mouse models, and small animal models are used not only to generate the antibodies, but also as a platform for further optimization and testing of the biologics. Camelid-based antibodies, which have supe ...
SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Amyloid-Beta and Tau/Glycosaminoglycan Dual Inhibitor for Alzheimer's Disease
SBC: GISMO THERAPEUTICS INC. Topic: 100ABSTRACT The aim of this project is to support an IND application for GTC-3295 for the treatment of Alzheimer's Disease (AD). Neurodegenerative amyloid diseases such as AD have common underlying biochemical pathways leading to oligomerization and aggregation of amyloidogenic peptides and prion-like spreading of amyloid proteopathic seeds throughout the Central Nervous System (CNS). Recent data sug ...
SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Development of DYRK1A allosteric modulator for the treatment of Alzheimer's Disease
SBC: Avanti Biosciences Inc Topic: NIAPROJECT SUMMARYThis proposal aims to develop ABI-171, a potent and selective inhibitor of the “Dual-specificity tyrosine- (Y)-phosphorylation Regulated Kinase-1A” (DYRK1A), to treat mild to moderate Alzheimer’s disease (AD) because of its role in inflammation and phosphorylation of key target protein like Amyloid Precursor Protein (APP), Presenilin-1 (PS1), and tau.AD is a neurodegenerative ...
SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health